DM
JAZZ icon

Delphi Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Delphi Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,374
Closed -$1.25M – 85
2024
Q1 		$1.25M Sell
10,374
-527
-5% -$64.6K 0.97% 68
2023
Q4 		$1.34M Buy
10,901
+695
+7% +$86.7K 1.23% 54
2023
Q3 		$1.32M Buy
10,206
+12
+0.1% +$1.6K 1.35% 30
2023
Q2 		$1.26M Buy
+10,194
New +$1.37M 1.31% 37
2022
Q4 		$1.39M Buy
+8,697
New +$1.27M 1.68% 9
2021
Q4 		$701K Sell
5,502
-965
-15% -$127K 0.66% 73
2021
Q3 		$842K Sell
6,467
-708
-10% -$107K 0.87% 68
2021
Q2 		$1.27M Sell
7,175
-46
-0.6% -$7.97K 1.22% 29
2021
Q1 		$1.19M Buy
+7,221
New +$1.19M 1.26% 40

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Delphi Management's JAZZ Position: Q2 2024 in Review

Delphi Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 10,374 shares — an estimated $1.25M sold.

Delphi Management first reported a position in JAZZ in Q1 2021 and held it in 9 quarters. The position peaked at $1.39M in Q4 2022. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Delphi Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Delphi Management sold 10,374 Jazz Pharmaceuticals shares in Q2 2024, an estimated $1.25M.
  • Delphi Management first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • Delphi Management's Jazz Pharmaceuticals position peaked at $1.39M in Q4 2022.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Delphi Management's 13F filing for Q2 2024, filed 26 Aug 2024.